ArticleFrontiers in public health2024

Assessment of clinical benefit, cost and uptake of biosimilars versus reference biologics in immune-mediated inflammatory diseases in China.

Xin Du et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.